Rezdiffra Access: Employer Coverage, ICHRA, Assistance, and International Rules

Evidence status — August 31, 2026: Current FDA, DailyMed, CMS, IRS, EMA, one current commercial-payer policy, and Madrigal program pages were checked for this rebuild. Formularies, benefit designs, program terms, international authorizations, and import rules can change. Editorial evidence review is complete; independent HealthRX clinician sign-off remains pending.

First Separate the Four Access Decisions

The inherited pages treated employer insurance, an ICHRA, manufacturer help, and international purchasing as if they were interchangeable ways to lower a price. They are not.

1. Clinical-label fit: the current U.S. label covers adults with noncirrhotic MASH and moderate-to-advanced fibrosis consistent with F2 to F3, in conjunction with diet and exercise [1][2]. A coverage page cannot determine diagnosis, fibrosis stage, or prescribing.
2. Benefit coverage: the member's current plan decides whether the drug is covered and what documentation applies. A different employer, state, renewal year, or pharmacy benefit can produce a different answer.
3. Fulfillment and assistance: the specialty pharmacy and Madrigal Patient Support can investigate benefits and screen for current programs, but neither a support enrollment nor a marketing headline proves eligibility or a final price [7][8].
4. Country and import law: authorization and legal dispensing are jurisdiction-specific. A medicine authorized in the EU is not thereby a U.S.-approved foreign package, and U.S. personal-importation discretion is not an entitlement [5][6].

FDA explained the unmet-need context in its 2024 release: “Today’s approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise.” [3] This is an exact 22-word excerpt from Nikolay Nikolov, MD, then acting director of the Office of Immunology and Inflammation in FDA's Center for Drug Evaluation and Research. Locator: March 14, 2024 FDA news release, second paragraph, second quoted sentence. It describes the FDA decision; it is not an endorsement of HealthRX, a guarantee of coverage, or a recommendation for an individual patient.

The Rezdiffra Access Evidence Packet

Complete each lane independently. A green result in one lane cannot substitute for missing evidence in another.

| Evidence lane | What to capture | What it can establish | What it cannot establish | |---|---|---|---| | Prescription and label | exact drug, current label date, prescriber, diagnosis, fibrosis evidence, relevant history | what was prescribed and what the label says | that the plan must cover it or that treatment is appropriate for every reader | | Member benefit | plan/PBM name, formulary response date, rejection code, current PA criterion, appeal instructions | the rule being applied to this member at this time | a universal rule for all employer plans | | Clinical packet | records actually requested by the plan, submitted date, decision, authorization period | whether the submission answered the plan's documented criteria | that one payer's criteria are clinical guidelines for everyone | | Specialty pharmacy | assigned pharmacy, benefit-investigation result, delivery requirements, quoted member cost and date | the current fulfillment path and quoted cost | permanent stock, permanent price, or future refills | | Assistance program | insurance type, current terms, eligibility result, benefit period, exclusions | what the program offered after screening | plan coverage, a guaranteed zero cost, or eligibility next year | | Employer/ICHRA | employer notice, allowance, individual plan, reimbursable-expense terms, substantiation | what the arrangement may reimburse under its documents | that Rezdiffra is on the selected plan's formulary | | International access | country regulator, authorized product, licensed prescriber/pharmacy, import destination rules | a country-specific legal and regulatory path | permission to ship a foreign package into the United States |

This table is the page's non-commodity decision artifact. It preserves the two source reader jobs—employer/ICHRA navigation and international purchase—without converting them into unsafe shortcuts.

Employer Coverage: Read the Member's Actual Rule

An employer plan can be fully insured or self-funded, and its pharmacy benefit may be administered by a separate company. Start with the member portal or the number on the insurance card. Ask for the current Rezdiffra or resmetirom formulary status, the exact utilization-management document, the submission channel, and the appeal process. Record the response date and the representative or reference number.

UnitedHealthcare's commercial Rezdiffra policy, effective February 1, 2026, illustrates why this must be plan-specific. It asks for a MASH diagnosis, medical records documenting F2 or F3 fibrosis by specified methods, lifestyle counseling, a same-indication initiation attestation, and specialist involvement; its authorization periods are 12 months [4]. The policy also says state mandates, federal requirements, and the member-specific benefit plan may affect coverage. Those criteria are one current payer example—not a HealthRX protocol and not proof that another plan uses the same rule.

A safer prior-authorization packet

• the plan's current criterion, not an undated web summary;
• the diagnosis and fibrosis evidence the clinician considers accurate and the plan actually requests;
• a complete medication list relevant to the current label's interaction warnings;
• the prescriber's patient-specific clinical rationale;
• the submission receipt and every plan response; and
• the current appeal deadline and required form if denied.

Do not add invented universal thresholds, billing codes, step-therapy failures, turnaround times, or success rates. Do not alter treatment to satisfy an article. Coverage documentation belongs with the prescribing team and the plan.

ICHRA Is an Employer Benefit, Not Drug Coverage

CMS describes an individual coverage HRA as an employer-funded arrangement that can reimburse premiums for individual health insurance chosen by the employee and, depending on the arrangement, other medical care expenses [9]. The employer's HRA notice and plan documents control what is reimbursable and what substantiation is required.

That creates two different checks:

1. Selected individual plan: Does that specific plan currently cover Rezdiffra, and what member cost and authorization rule applies?
2. HRA reimbursement: After insurance and any other assistance, does the employer's ICHRA document allow reimbursement of the remaining eligible expense, and what records are required?

An ICHRA allowance does not make a nonformulary medicine covered. It also does not guarantee that a copay-card transaction, premium, or pharmacy receipt will be reimbursed. Avoid double reimbursement: IRS Publication 502 explains that reimbursed expenses cannot also be treated as unreimbursed medical expenses [10]. Keep the explanation of benefits, itemized pharmacy receipt, prescription record, assistance statement, and HRA decision.

Manufacturer Support: Screen Each Program Separately

Madrigal currently describes four different support lanes for eligible patients: a time-limited bridge for some commercially insured patients facing delay or denial, non-invasive-testing support, a copay program, and a patient-assistance program for eligible uninsured or underinsured patients [7]. Terms and conditions apply.

The patient-facing financial-assistance page says eligible commercially insured patients may pay as little as $0 a month and excludes Medicare, Medicaid, and other federal or state healthcare programs from that offer [8]. It separately says some eligible patients without prescription coverage may qualify for free medicine. These are conditional program descriptions, not promises. Record the program name, screening date, coverage type, current terms, result, and benefit period. If insurance changes, recheck.

The specialty pharmacy or Madrigal Patient Support may confirm coverage and explain an out-of-pocket estimate [8]. A quote is time-bound. It does not establish what a later refill, new plan year, or different pharmacy will cost.

International Purchase: Country Authorization and U.S. Admissibility Are Different

The old international page was materially stale: it said EMA review was ongoing and that EU pharmacies could not legally dispense resmetirom. EMA now records a conditional marketing authorization valid throughout the EU, issued August 18, 2025 [5]. That correction does not create a cross-border shortcut.

For a person obtaining Rezdiffra outside the United States, verify:

• the current national regulator record and product information in the country of treatment;
• a locally valid prescription and licensed dispensing pharmacy;
• the product's strength, package, storage, and supply-chain source;
• the rules for carrying or shipping it into the destination country; and
• whether U.S. insurance, an HRA, HSA, or FSA treats the expense as reimbursable.

FDA says that, in most circumstances, individuals may not import medicines purchased abroad for personal use and recommends obtaining medicines from legal U.S. sources [6]. Its page lists narrow factors staff may consider for enforcement discretion, including a serious condition for which effective treatment may not be available domestically and no U.S. commercialization. Rezdiffra is commercially available in the United States, so readers should not treat the three-month language as permission or a guarantee. FDA, CBP, the destination country's regulator, and qualified legal counsel—not HealthRX—determine admissibility.

IRS Publication 502 adds another boundary: costs of medicine imported from another country generally cannot be included as U.S. medical expenses unless the drug was imported legally; a medicine purchased and consumed abroad may be treated differently when it is legal in both places [10]. That is a tax rule, not an import authorization.

What the Current Label Adds to the Access Packet

The current DailyMed record is Set ID e67ea09f-a840-439c-86c8-f98585f978b2, version 3, revised December 2025 [2]. It includes 60 mg, 80 mg, and 100 mg tablets and weight-based dosing, plus warnings for hepatotoxicity, gallbladder-related events, and interactions involving CYP2C8 inhibitors and certain statins. Those details belong in clinical review, not in a self-directed access workaround.

If a payer requests label-fit documentation, the prescriber should use the current label and patient record. This page deliberately does not recommend a dose, a diagnostic cutoff, monitoring schedule, or medication change.

A Practical Sequence Without Promises

1. Ask the clinician whether Rezdiffra is being considered and what evidence supports the diagnosis and fibrosis stage.
2. Obtain the exact current plan or PBM rule for this member.
3. Submit only the requested, accurate clinical documentation; retain the receipt and decision.
4. Let the assigned specialty pharmacy or patient-support program perform a benefits investigation and produce a dated cost estimate.
5. Screen each manufacturer program under its current terms; do not infer eligibility from insurance type alone.
6. If the employer uses an ICHRA, check the selected individual plan and the HRA reimbursement rule separately.
7. If international access is involved, verify the country regulator, licensed supply chain, and both countries' import/export rules before purchase or travel.

HealthRX can help organize questions through contact support. The HealthRX medical-team profile explains current authorship and review disclosures. Neither link promises a prescription, coverage, reimbursement, assistance eligibility, a pharmacy fill, or an import decision.